Publications

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2018.  A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.. Clin Cancer Res.

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopolou E, Chakravarthi BV, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 3(22):298-305.

Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, Krupa R, Graf RP, Schreiber NA, Nanus DM et al..  2016.  The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.. Clin Cancer Res. 6(22)

Beltran H.  2013.  DNA mismatch repair in prostate cancer.. J Clin Oncol. 31(14):1782-4.

Beltran H.  2014.  The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential.. Mol Cancer Res. 12(6):815-22.

Beltran H, Park K, Tagawa ST, Yelensky R, Lipson D, Frampton G, Stephens PJ, Cronin MT, Nanus DM, Mosquera JMiguel et al..  2012.  Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.. J Clin Oncol. 30(5_suppl):110.

Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H et al..  2014.  Aggressive variants of castration-resistant prostate cancer.. Clin Cancer Res. 20(11):2846-50.

Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, Rubin MA, Nanus DM.  2012.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.. J Clin Oncol. 30(36):386-9.

Beltran H, Kaur G, de España CGarcías, Tagawa ST.  2014.  Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib.. Asian J Androl. 16(4):568-9.

Beltran H, Park K, Tagawa ST, Macdonald T, Nanus DM, Mosquera JMiguel, Rubin MA.  2012.  Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).. J Clin Oncol. 30(5_suppl):120.

Beltran H, Yelensky R, Frampton GM, Park K, , MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM et al..  2013.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.. Eur Urol. 63(5):920-6.

Beltran H, Rubin MA.  2013.  New strategies in prostate cancer: translating genomics into the clinic.. Clin Cancer Res. 19(3):517-23.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.

Beltran H, Antonarakis ES, Morris MJ, Attard G.  2016.  Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.. Am Soc Clin Oncol Educ Book. (35):131-41.

Beltran H, Demichelis F.  2015.  Prostate cancer: Intrapatient heterogeneity in prostate cancer.. Nat Rev Urol. 12(8):430-1.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Attard G, Beltran H.  2015.  Prioritizing precision medicine for prostate cancer.. Ann Oncol. 26(6):1041-2.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, G Han C, Coleman I et al..  2018.  The long tail of oncogenic drivers in prostate cancer.. Nat Genet. 50(5):645-651.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A et al..  2015.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.. Cell Rep. 12(6):922-36.